U.S., March 7 -- ClinicalTrials.gov registry received information related to the study (NCT07455955) titled 'Personalized Antiemetic Regimen According to Patients' Pharmacogenetic Profile' on March 03.
Brief Summary: The objectives of this study are to determine if pharmacogenetic (PG) analysis of an individual enable optimal selection of antiemetic regimen for patients undergoing the first cycle of AC or FEC chemotherapy. It also aims to compare the quality of life of patients in the first cycle of AC / FEC chemotherapy with and without PG analysis.
Patients will be ramzdomized to undergo PG analysis [PG group] versus no PG analysis [Non-+PG group]. Those in the PG group would be offered currently available optimal antiemetic prophylaxis...